Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Adrenomedullin peptides and antibodies, which would be useful in the development of a therapeutic or for diagnostics use More
Photodynamic Therapy of Cervical Cancer, Cervical Dysplasia and HPV Infection More
Glycan Microarray Devices for Quantitative Detection Analysis of Cancer More
Molecular Diagnostics for Breast Cancer Precursors More
Elucidation of a Novel Biomarker to Predict Resistance to Doxorubicin Cancer Therapy More
P38MAPK as a Marker for Predicting Tamoxifen Resistance More
Clinical Applications of Serum HtrA1 as Markers for Pre-Eclampsia, Osteoarthritis and Cardiovascular Diseases More
Biomarkers for Breast Cancer Based on Genetic Instability More
Cervical Cancer Screening: New Diagnostic for the Detection of the HPV E7 Oncoprotein in Cervical Biopsies and in Ectocervical Smears More
Detection of Early Changes in Foetal EEG Due to Asphyxia with Acidemia During Labour More
Related Reports
Market Research Reports provided by reports.iptechex.com
May 2011 - 102 pages - $3,835
Apr 2011 - 951 pages - $4,995
Dec 2011 - 50 pages - $3,800
Nov 2011 - 50 pages - $3,800
Jan 2011 - 45 pages - $5,700
Aug 2007 - 87 pages - $1,999
Aug 2008 - 352 pages - $2,615
Jan 2007 - 90 pages - $1,995
Apr 2011 - 150 pages - $3,995
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
Apr 2008 - 265 pages - $3,835
Your selection
Browse By
- Therapeutic target
- Amenorrhea
- Contraception, female
- Dysmenorrhea
- Dysoplasia, cervical
- Endometriosis
- Female arousal disorder
- Gynecological disorder (other)
- Menopause
- Pelvic inflammatory disease
- Polycystic ovary syndrome
- Pregnancy
- Sjogren's syndrome
- Turner's syndrome
- Women's health (other)
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us